This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
This explains the function of the index divisor for investors, including how it influences observed returns and analysis.
26,233 articlesA GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Alphabet ramps up AI-enabled cloud expansion and heavy spending, fueling the debate over whether it can become the ne...
Canopy Growth sits at the center of sharp investor debate. This article maps three plausible paths for the stock over...
Long-dated U.S. Treasuries saw muted appetite from investors as inflation remains stubborn and energy risks persist. ...
Quantum names showed a broad pullback after a sharp rally, with IonQ down about 7% and D-Wave slipping near 8% as inv...
As tax policy and markets evolve, the math that makes these dividend stocks tax-smart remains a compelling lever for ...
Marvell Technology is set to report fiscal Q1 results after the close, with investors weighing AI demand, margins and...
Gorilla's Q1 2026 results shed light on the company’s growth trajectory and profitability path. This deep dive breaks...
Intel overcame a tough 12 months to deliver a striking rebound. Analysts say the AI-led strategy and foundry expansio...
As investors chase high yields, the location of the account matters. In a taxable setup, $60,000 of ordinary-income d...
Tech stocks lead market declines as traders weigh higher-for-longer rates against cooling AI chip enthusiasm and a su...
Zscaler’s latest quarter reinforces a bold security thesis: billions of AI agents will need protection, a theme that ...